Mod­er­na bur­nish­es its PhI­II-ready Covid-19 vac­cine with promis­ing mouse da­ta — which sug­gest one dose might be enough af­ter all

Mod­er­na and the NIH didn’t wait for an­i­mal da­ta to be­gin test­ing its mR­NA vac­cine can­di­date in pa­tients. But on the same day they un­veiled plans for an ul­tra-fast Phase III in Ju­ly, sci­en­tists al­so re­leased mouse da­ta that they say back up and in­form the piv­otal study.

In a preprint, the com­bined team from An­tho­ny Fau­ci-led NI­AID and Mod­er­na’s in­fec­tious dis­ease unit re­port­ed their vac­cine gen­er­at­ed “po­tent neu­tral­iz­ing ac­tiv­i­ty” and ap­peared to pro­tect mice from a vi­ral in­fec­tion up to 13 weeks post-in­jec­tion. Per­haps more im­por­tant­ly, no safe­ty sig­nals emerged when they chal­lenged the mice with the coro­n­avirus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.